Naloxone is an opioid antagonist licenced for use in:
- Treatment of suspected acute opioid overdose or intoxication; and
- Complete or partial reversal of central nervous system depression and especially respiratory depression, caused by natural or synthetic opioids
This policy is relevant to: Inpatient Pain Service, Supportive and Palliative care Service, Registered Nurses, Operating Department Practitioners (ODPs), Doctors, Non-Medical Prescribers, Pharmacy, Resuscitation Team, Outreach Team (not an exhaustive list).
The purpose of this policy is to outline how to safely prescribe and administer naloxone to patients who have either acute opioid overdose or acute opioid respiratory depression and sedation in those receiving postoperative opioids, palliative care and in chronic opioid use.
|Compiled by:||Harriet Barker, Lead Nurse Pain Services|
|Ratified by:||Drugs and Therapeutics Committee|
|Date Ratified:||March 2019|
|Date Issued:||April 2019|
|Review Date:||March 2022|
|Target Audience:||All staff|
|Contact name:||Harriet Barker, Lead Nurse Pain Services|
- Medicines Management Policy
- Administration of Injectable Medicines Policy